Vaccine for Influenza market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Vaccine for Influenza market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type Trivalent Influenza Vaccine Quadrivalent Influenza Vaccine Segment by Application For Children (6 months to 3 years) For Adults and Children over 3 years By Company Sanofi CSL GSK Mylan Hulan Bio AstraZeneca CCBIO By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE
1 Study Coverage 1.1 Vaccine for Influenza Product Introduction 1.2 Market by Type 1.2.1 Global Vaccine for Influenza Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Trivalent Influenza Vaccine 1.2.3 Quadrivalent Influenza Vaccine 1.3 Market by Application 1.3.1 Global Vaccine for Influenza Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 For Children (6 months to 3 years) 1.3.3 For Adults and Children over 3 years 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Vaccine for Influenza Sales Estimates and Forecasts 2017-2028 2.2 Global Vaccine for Influenza Revenue Estimates and Forecasts 2017-2028 2.3 Global Vaccine for Influenza Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global Vaccine for Influenza Sales by Region 2.4.1 Global Vaccine for Influenza Sales by Region (2017-2022) 2.4.2 Global Sales Vaccine for Influenza by Region (2023-2028) 2.5 Global Vaccine for Influenza Revenue by Region 2.5.1 Global Vaccine for Influenza Revenue by Region (2017-2022) 2.5.2 Global Vaccine for Influenza Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Vaccine for Influenza Sales by Manufacturers 3.1.1 Global Top Vaccine for Influenza Manufacturers by Sales (2017-2022) 3.1.2 Global Vaccine for Influenza Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaccine for Influenza in 2021 3.2 Global Vaccine for Influenza Revenue by Manufacturers 3.2.1 Global Vaccine for Influenza Revenue by Manufacturers (2017-2022) 3.2.2 Global Vaccine for Influenza Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by Vaccine for Influenza Revenue in 2021 3.3 Global Vaccine for Influenza Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Vaccine for Influenza Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Vaccine for Influenza Sales by Type 4.1.1 Global Vaccine for Influenza Historical Sales by Type (2017-2022) 4.1.2 Global Vaccine for Influenza Forecasted Sales by Type (2023-2028) 4.1.3 Global Vaccine for Influenza Sales Market Share by Type (2017-2028) 4.2 Global Vaccine for Influenza Revenue by Type 4.2.1 Global Vaccine for Influenza Historical Revenue by Type (2017-2022) 4.2.2 Global Vaccine for Influenza Forecasted Revenue by Type (2023-2028) 4.2.3 Global Vaccine for Influenza Revenue Market Share by Type (2017-2028) 4.3 Global Vaccine for Influenza Price by Type 4.3.1 Global Vaccine for Influenza Price by Type (2017-2022) 4.3.2 Global Vaccine for Influenza Price Forecast by Type (2023-2028) 5 Market Size by Application 5.1 Global Vaccine for Influenza Sales by Application 5.1.1 Global Vaccine for Influenza Historical Sales by Application (2017-2022) 5.1.2 Global Vaccine for Influenza Forecasted Sales by Application (2023-2028) 5.1.3 Global Vaccine for Influenza Sales Market Share by Application (2017-2028) 5.2 Global Vaccine for Influenza Revenue by Application 5.2.1 Global Vaccine for Influenza Historical Revenue by Application (2017-2022) 5.2.2 Global Vaccine for Influenza Forecasted Revenue by Application (2023-2028) 5.2.3 Global Vaccine for Influenza Revenue Market Share by Application (2017-2028) 5.3 Global Vaccine for Influenza Price by Application 5.3.1 Global Vaccine for Influenza Price by Application (2017-2022) 5.3.2 Global Vaccine for Influenza Price Forecast by Application (2023-2028) 6 North America 6.1 North America Vaccine for Influenza Market Size by Type 6.1.1 North America Vaccine for Influenza Sales by Type (2017-2028) 6.1.2 North America Vaccine for Influenza Revenue by Type (2017-2028) 6.2 North America Vaccine for Influenza Market Size by Application 6.2.1 North America Vaccine for Influenza Sales by Application (2017-2028) 6.2.2 North America Vaccine for Influenza Revenue by Application (2017-2028) 6.3 North America Vaccine for Influenza Market Size by Country 6.3.1 North America Vaccine for Influenza Sales by Country (2017-2028) 6.3.2 North America Vaccine for Influenza Revenue by Country (2017-2028) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe Vaccine for Influenza Market Size by Type 7.1.1 Europe Vaccine for Influenza Sales by Type (2017-2028) 7.1.2 Europe Vaccine for Influenza Revenue by Type (2017-2028) 7.2 Europe Vaccine for Influenza Market Size by Application 7.2.1 Europe Vaccine for Influenza Sales by Application (2017-2028) 7.2.2 Europe Vaccine for Influenza Revenue by Application (2017-2028) 7.3 Europe Vaccine for Influenza Market Size by Country 7.3.1 Europe Vaccine for Influenza Sales by Country (2017-2028) 7.3.2 Europe Vaccine for Influenza Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Vaccine for Influenza Market Size by Type 8.1.1 Asia Pacific Vaccine for Influenza Sales by Type (2017-2028) 8.1.2 Asia Pacific Vaccine for Influenza Revenue by Type (2017-2028) 8.2 Asia Pacific Vaccine for Influenza Market Size by Application 8.2.1 Asia Pacific Vaccine for Influenza Sales by Application (2017-2028) 8.2.2 Asia Pacific Vaccine for Influenza Revenue by Application (2017-2028) 8.3 Asia Pacific Vaccine for Influenza Market Size by Region 8.3.1 Asia Pacific Vaccine for Influenza Sales by Region (2017-2028) 8.3.2 Asia Pacific Vaccine for Influenza Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 China Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 9 Latin America 9.1 Latin America Vaccine for Influenza Market Size by Type 9.1.1 Latin America Vaccine for Influenza Sales by Type (2017-2028) 9.1.2 Latin America Vaccine for Influenza Revenue by Type (2017-2028) 9.2 Latin America Vaccine for Influenza Market Size by Application 9.2.1 Latin America Vaccine for Influenza Sales by Application (2017-2028) 9.2.2 Latin America Vaccine for Influenza Revenue by Application (2017-2028) 9.3 Latin America Vaccine for Influenza Market Size by Country 9.3.1 Latin America Vaccine for Influenza Sales by Country (2017-2028) 9.3.2 Latin America Vaccine for Influenza Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Vaccine for Influenza Market Size by Type 10.1.1 Middle East and Africa Vaccine for Influenza Sales by Type (2017-2028) 10.1.2 Middle East and Africa Vaccine for Influenza Revenue by Type (2017-2028) 10.2 Middle East and Africa Vaccine for Influenza Market Size by Application 10.2.1 Middle East and Africa Vaccine for Influenza Sales by Application (2017-2028) 10.2.2 Middle East and Africa Vaccine for Influenza Revenue by Application (2017-2028) 10.3 Middle East and Africa Vaccine for Influenza Market Size by Country 10.3.1 Middle East and Africa Vaccine for Influenza Sales by Country (2017-2028) 10.3.2 Middle East and Africa Vaccine for Influenza Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia 11 Company Profiles 11.1 Sanofi 11.1.1 Sanofi Corporation Information 11.1.2 Sanofi Overview 11.1.3 Sanofi Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Sanofi Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Sanofi Recent Developments 11.2 CSL 11.2.1 CSL Corporation Information 11.2.2 CSL Overview 11.2.3 CSL Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 CSL Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 CSL Recent Developments 11.3 GSK 11.3.1 GSK Corporation Information 11.3.2 GSK Overview 11.3.3 GSK Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.3.4 GSK Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.3.5 GSK Recent Developments 11.4 Mylan 11.4.1 Mylan Corporation Information 11.4.2 Mylan Overview 11.4.3 Mylan Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.4.4 Mylan Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.4.5 Mylan Recent Developments 11.5 Hulan Bio 11.5.1 Hulan Bio Corporation Information 11.5.2 Hulan Bio Overview 11.5.3 Hulan Bio Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.5.4 Hulan Bio Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.5.5 Hulan Bio Recent Developments 11.6 AstraZeneca 11.6.1 AstraZeneca Corporation Information 11.6.2 AstraZeneca Overview 11.6.3 AstraZeneca Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.6.4 AstraZeneca Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.6.5 AstraZeneca Recent Developments 11.7 CCBIO 11.7.1 CCBIO Corporation Information 11.7.2 CCBIO Overview 11.7.3 CCBIO Vaccine for Influenza Sales, Price, Revenue and Gross Margin (2017-2022) 11.7.4 CCBIO Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications 11.7.5 CCBIO Recent Developments 12 Industry Chain and Sales Channels Analysis 12.1 Vaccine for Influenza Industry Chain Analysis 12.2 Vaccine for Influenza Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Vaccine for Influenza Production Mode & Process 12.4 Vaccine for Influenza Sales and Marketing 12.4.1 Vaccine for Influenza Sales Channels 12.4.2 Vaccine for Influenza Distributors 12.5 Vaccine for Influenza Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Vaccine for Influenza Industry Trends 13.2 Vaccine for Influenza Market Drivers 13.3 Vaccine for Influenza Market Challenges 13.4 Vaccine for Influenza Market Restraints 14 Key Findings in The Global Vaccine for Influenza Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer
List of Tables Table 1. Global Vaccine for Influenza Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Trivalent Influenza Vaccine Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine Table 4. Global Vaccine for Influenza Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 5. Global Vaccine for Influenza Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million) Table 6. Global Vaccine for Influenza Sales by Region (2017-2022) & (K Units) Table 7. Global Vaccine for Influenza Sales Market Share by Region (2017-2022) Table 8. Global Vaccine for Influenza Sales by Region (2023-2028) & (K Units) Table 9. Global Vaccine for Influenza Sales Market Share by Region (2023-2028) Table 10. Global Vaccine for Influenza Revenue by Region (2017-2022) & (US$ Million) Table 11. Global Vaccine for Influenza Revenue Market Share by Region (2017-2022) Table 12. Global Vaccine for Influenza Revenue by Region (2023-2028) & (US$ Million) Table 13. Global Vaccine for Influenza Revenue Market Share by Region (2023-2028) Table 14. Global Vaccine for Influenza Sales by Manufacturers (2017-2022) & (K Units) Table 15. Global Vaccine for Influenza Sales Share by Manufacturers (2017-2022) Table 16. Global Vaccine for Influenza Revenue by Manufacturers (2017-2022) & (US$ Million) Table 17. Global Vaccine for Influenza Revenue Share by Manufacturers (2017-2022) Table 18. Vaccine for Influenza Price by Manufacturers (2017-2022) &(US$/Unit) Table 19. Global Vaccine for Influenza Manufacturers Market Concentration Ratio (CR5 and HHI) Table 20. Global Vaccine for Influenza by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2021) Table 21. Vaccine for Influenza Manufacturing Base Distribution and Headquarters Table 22. Manufacturers Vaccine for Influenza Product Offered Table 23. Date of Manufacturers Enter into Vaccine for Influenza Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 26. Global Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 27. Global Vaccine for Influenza Sales Share by Type (2017-2022) Table 28. Global Vaccine for Influenza Sales Share by Type (2023-2028) Table 29. Global Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 30. Global Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 31. Global Vaccine for Influenza Revenue Share by Type (2017-2022) Table 32. Global Vaccine for Influenza Revenue Share by Type (2023-2028) Table 33. Vaccine for Influenza Price by Type (2017-2022) & (US$/Unit) Table 34. Global Vaccine for Influenza Price Forecast by Type (2023-2028) & (US$/Unit) Table 35. Global Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 36. Global Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 37. Global Vaccine for Influenza Sales Share by Application (2017-2022) Table 38. Global Vaccine for Influenza Sales Share by Application (2023-2028) Table 39. Global Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 40. Global Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 41. Global Vaccine for Influenza Revenue Share by Application (2017-2022) Table 42. Global Vaccine for Influenza Revenue Share by Application (2023-2028) Table 43. Vaccine for Influenza Price by Application (2017-2022) & (US$/Unit) Table 44. Global Vaccine for Influenza Price Forecast by Application (2023-2028) & (US$/Unit) Table 45. North America Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 46. North America Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 47. North America Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 48. North America Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 49. North America Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 50. North America Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 51. North America Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 52. North America Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 53. North America Vaccine for Influenza Sales by Country (2017-2022) & (K Units) Table 54. North America Vaccine for Influenza Sales by Country (2023-2028) & (K Units) Table 55. North America Vaccine for Influenza Revenue by Country (2017-2022) & (US$ Million) Table 56. North America Vaccine for Influenza Revenue by Country (2023-2028) & (US$ Million) Table 57. Europe Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 58. Europe Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 59. Europe Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 60. Europe Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 61. Europe Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 62. Europe Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 63. Europe Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 64. Europe Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 65. Europe Vaccine for Influenza Sales by Country (2017-2022) & (K Units) Table 66. Europe Vaccine for Influenza Sales by Country (2023-2028) & (K Units) Table 67. Europe Vaccine for Influenza Revenue by Country (2017-2022) & (US$ Million) Table 68. Europe Vaccine for Influenza Revenue by Country (2023-2028) & (US$ Million) Table 69. Asia Pacific Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 70. Asia Pacific Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 71. Asia Pacific Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 72. Asia Pacific Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 73. Asia Pacific Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 74. Asia Pacific Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 75. Asia Pacific Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 76. Asia Pacific Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 77. Asia Pacific Vaccine for Influenza Sales by Region (2017-2022) & (K Units) Table 78. Asia Pacific Vaccine for Influenza Sales by Region (2023-2028) & (K Units) Table 79. Asia Pacific Vaccine for Influenza Revenue by Region (2017-2022) & (US$ Million) Table 80. Asia Pacific Vaccine for Influenza Revenue by Region (2023-2028) & (US$ Million) Table 81. Latin America Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 82. Latin America Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 83. Latin America Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 84. Latin America Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 85. Latin America Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 86. Latin America Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 87. Latin America Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 88. Latin America Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 89. Latin America Vaccine for Influenza Sales by Country (2017-2022) & (K Units) Table 90. Latin America Vaccine for Influenza Sales by Country (2023-2028) & (K Units) Table 91. Latin America Vaccine for Influenza Revenue by Country (2017-2022) & (US$ Million) Table 92. Latin America Vaccine for Influenza Revenue by Country (2023-2028) & (US$ Million) Table 93. Middle East and Africa Vaccine for Influenza Sales by Type (2017-2022) & (K Units) Table 94. Middle East and Africa Vaccine for Influenza Sales by Type (2023-2028) & (K Units) Table 95. Middle East and Africa Vaccine for Influenza Revenue by Type (2017-2022) & (US$ Million) Table 96. Middle East and Africa Vaccine for Influenza Revenue by Type (2023-2028) & (US$ Million) Table 97. Middle East and Africa Vaccine for Influenza Sales by Application (2017-2022) & (K Units) Table 98. Middle East and Africa Vaccine for Influenza Sales by Application (2023-2028) & (K Units) Table 99. Middle East and Africa Vaccine for Influenza Revenue by Application (2017-2022) & (US$ Million) Table 100. Middle East and Africa Vaccine for Influenza Revenue by Application (2023-2028) & (US$ Million) Table 101. Middle East and Africa Vaccine for Influenza Sales by Country (2017-2022) & (K Units) Table 102. Middle East and Africa Vaccine for Influenza Sales by Country (2023-2028) & (K Units) Table 103. Middle East and Africa Vaccine for Influenza Revenue by Country (2017-2022) & (US$ Million) Table 104. Middle East and Africa Vaccine for Influenza Revenue by Country (2023-2028) & (US$ Million) Table 105. Sanofi Corporation Information Table 106. Sanofi Description and Major Businesses Table 107. Sanofi Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 108. Sanofi Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 109. Sanofi Recent Developments Table 110. CSL Corporation Information Table 111. CSL Description and Major Businesses Table 112. CSL Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 113. CSL Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 114. CSL Recent Developments Table 115. GSK Corporation Information Table 116. GSK Description and Major Businesses Table 117. GSK Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 118. GSK Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 119. GSK Recent Developments Table 120. Mylan Corporation Information Table 121. Mylan Description and Major Businesses Table 122. Mylan Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 123. Mylan Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 124. Mylan Recent Developments Table 125. Hulan Bio Corporation Information Table 126. Hulan Bio Description and Major Businesses Table 127. Hulan Bio Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 128. Hulan Bio Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 129. Hulan Bio Recent Developments Table 130. AstraZeneca Corporation Information Table 131. AstraZeneca Description and Major Businesses Table 132. AstraZeneca Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 133. AstraZeneca Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 134. AstraZeneca Recent Developments Table 135. CCBIO Corporation Information Table 136. CCBIO Description and Major Businesses Table 137. CCBIO Vaccine for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 138. CCBIO Vaccine for Influenza Product Model Numbers, Pictures, Descriptions and Specifications Table 139. CCBIO Recent Developments Table 140. Key Raw Materials Lists Table 141. Raw Materials Key Suppliers Lists Table 142. Vaccine for Influenza Distributors List Table 143. Vaccine for Influenza Customers List Table 144. Vaccine for Influenza Market Trends Table 145. Vaccine for Influenza Market Drivers Table 146. Vaccine for Influenza Market Challenges Table 147. Vaccine for Influenza Market Restraints Table 148. Research Programs/Design for This Report Table 149. Key Data Information from Secondary Sources Table 150. Key Data Information from Primary Sources List of Figures Figure 1. Vaccine for Influenza Product Picture Figure 3. Global Vaccine for Influenza Market Share by Type in 2021 & 2028 Figure 3. Trivalent Influenza Vaccine Product Picture Figure 4. Quadrivalent Influenza Vaccine Product Picture Figure 5. Global Vaccine for Influenza Market Share by Application in 2021 & 2028 Figure 6. For Children (6 months to 3 years) Figure 7. For Adults and Children over 3 years Figure 8. Vaccine for Influenza Report Years Considered Figure 9. Global Vaccine for Influenza Sales 2017-2028 (K Units) Figure 10. Global Vaccine for Influenza Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Vaccine for Influenza Revenue 2017-2028 (US$ Million) Figure 12. Global Vaccine for Influenza Revenue Market Share by Region in Percentage: 2021 Versus 2028 Figure 13. Global Vaccine for Influenza Sales Market Share by Region (2017-2022) Figure 14. Global Vaccine for Influenza Sales Market Share by Region (2023-2028) Figure 15. North America Vaccine for Influenza Sales YoY (2017-2028) & (K Units) Figure 16. North America Vaccine for Influenza Revenue YoY (2017-2028) & (US$ Million) Figure 17. Europe Vaccine for Influenza Sales YoY (2017-2028) & (K Units) Figure 18. Europe Vaccine for Influenza Revenue YoY (2017-2028) & (US$ Million) Figure 19. Asia-Pacific Vaccine for Influenza Sales YoY (2017-2028) & (K Units) Figure 20. Asia-Pacific Vaccine for Influenza Revenue YoY (2017-2028) & (US$ Million) Figure 21. Latin America Vaccine for Influenza Sales YoY (2017-2028) & (K Units) Figure 22. Latin America Vaccine for Influenza Revenue YoY (2017-2028) & (US$ Million) Figure 23. Middle East & Africa Vaccine for Influenza Sales YoY (2017-2028) & (K Units) Figure 24. Middle East & Africa Vaccine for Influenza Revenue YoY (2017-2028) & (US$ Million) Figure 25. The Vaccine for Influenza Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021 Figure 26. The Top 5 and 10 Largest Manufacturers of Vaccine for Influenza in the World: Market Share by Vaccine for Influenza Revenue in 2021 Figure 27. Global Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021 Figure 28. Global Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 29. Global Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 30. Global Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 31. Global Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 32. North America Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 33. North America Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 34. North America Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 35. North America Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 36. North America Vaccine for Influenza Sales Share by Country (2017-2028) Figure 37. North America Vaccine for Influenza Revenue Share by Country (2017-2028) Figure 38. U.S. Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 39. Canada Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 40. Europe Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 41. Europe Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 42. Europe Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 43. Europe Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 44. Europe Vaccine for Influenza Sales Share by Country (2017-2028) Figure 45. Europe Vaccine for Influenza Revenue Share by Country (2017-2028) Figure 46. Germany Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 47. France Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 48. U.K. Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 49. Italy Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 50. Russia Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 51. Asia Pacific Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 52. Asia Pacific Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 53. Asia Pacific Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 54. Asia Pacific Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 55. Asia Pacific Vaccine for Influenza Sales Share by Region (2017-2028) Figure 56. Asia Pacific Vaccine for Influenza Revenue Share by Region (2017-2028) Figure 57. China Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 58. Japan Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 59. South Korea Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 60. India Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 61. Australia Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 62. China Taiwan Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 63. Indonesia Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 64. Thailand Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 65. Malaysia Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 66. Latin America Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 67. Latin America Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 68. Latin America Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 69. Latin America Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 70. Latin America Vaccine for Influenza Sales Share by Country (2017-2028) Figure 71. Latin America Vaccine for Influenza Revenue Share by Country (2017-2028) Figure 72. Mexico Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 73. Brazil Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 74. Argentina Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 75. Middle East and Africa Vaccine for Influenza Sales Market Share by Type (2017-2028) Figure 76. Middle East and Africa Vaccine for Influenza Revenue Market Share by Type (2017-2028) Figure 77. Middle East and Africa Vaccine for Influenza Sales Market Share by Application (2017-2028) Figure 78. Middle East and Africa Vaccine for Influenza Revenue Market Share by Application (2017-2028) Figure 79. Middle East and Africa Vaccine for Influenza Sales Share by Country (2017-2028) Figure 80. Middle East and Africa Vaccine for Influenza Revenue Share by Country (2017-2028) Figure 81. Turkey Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 82. Saudi Arabia Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 83. UAE Vaccine for Influenza Revenue (2017-2028) & (US$ Million) Figure 84. Vaccine for Influenza Value Chain Figure 85. Vaccine for Influenza Production Process Figure 86. Channels of Distribution Figure 87. Distributors Profiles Figure 88. Bottom-up and Top-down Approaches for This Report Figure 89. Data Triangulation Figure 90. Key Executives Interviewed